Not currently scheduled. To be notified when this course is running, please subscribe to our Events and Training Notifications.

Join us for an “Introduction to Economic Evaluation in Health”, conducted by experienced health economists from the Sydney Health Economics Collaboration (comprising the NHMRC Clinical Trials Centre, University of Sydney, UNSW, The George Institute).

The course will cover:

  • An introduction to economic concepts and the health technology assessment framework
  • An understanding of economic outcomes including utility-based quality of life
  • Estimation of total costs with a focus on routinely collected data
  • Calculation of cost effectiveness
  • An understanding of the policy process with regards to the Pharmaceutical Benefits Advisory Committee and the Medical Services Advisory Committee.

Who should attend?

Researchers, policymakers, clinicians and other health care workers with little to no experience in economic evaluation. No prior knowledge of economic evaluation is required.

About the presenter

This image has an empty alt attribute; its file name is rachael-morton-photo-150x150.jpg

Professor Rachael Morton is a Acting Deputy Director and Director of Health Economics & Health Technology Assessment at the NHMRC Clinical Trials Centre at the NHMRC Clinical Trials Centre, University of Sydney, and President of the Health Services Research Association of Australia and New Zealand (HSRAANZ).

Rachael specialises in trial-based and modelled economic evaluation, and elicitation of patient preferences using discrete choice experiments. Her research incorporates patient-centred and economic outcomes into clinical trials of diagnostic tests, new treatments and models of care to facilitate policy decision-making on the basis of cost-effectiveness.

Rachael has published more than 180 papers, advised several government bodies and committees including for the European Union, the Australian Government Department of Health as well as Australian state health departments, and the Economic Subcommittee of the Pharmaceutical Benefits Advisory Committee.